← Back to front page
United States · Business magazines · Fortune

Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements—and he won’t build them in China because ‘the IP is a massive worry’

Published by Fortune · United States 1 h ago
Kevin Lobo, chair and CEO of Stryker, onstage at the Fortune 500 Innovation Forum in Detroit
Kevin Lobo, chair and CEO of Stryker, onstage at the Fortune 500 Innovation Forum in Detroit · Fortune

Detailed summary

Kevin Lobo told Fortune that Chinese companies are “knocking off a lot of the other robots” as Stryker bets $400 million on a soft-tissue surgical robot.

Stryker builds every one of its orthopedic surgery robots in the U.S. CEO Kevin Lobo says it will stay that way, because of what’s happening in China.

“We have no plans to make any robots in China. The IP is a massive worry,” Lobo said Monday at the Fortune 500 Innovation Forum in Detroit. “They are knocking off a lot of the other robots.”

Robots are now central to how Stryker sells joint replacements. Lobo said two of every three Stryker knee replacements are now done robotically, using its Mako system, which has been used in 2.5 million procedures in 47 countries. That makes the robot’s intellectual property a big part of what Stryker is selling. Meanwhile, Chinese makers are scaling quickly. MicroPort MedBot, a Shanghai company that makes a soft-tissue surgical robot called Toumai, said in June that it had passed 300 global orders, was installed in more than 60 countries, and could build up to 500 robots a year.

Lobo, who is Stryker’s chair and CEO, said one of Stryker’s “major competitors” had bought into a Chinese robotics company. He didn’t say which one.

Fortune’s Andrew Nusca asked the panel what role the U.S. race with China plays in robotics: talent, intellectual property or supply chains. Lobo said Stryker makes its robots at home and ships them around the world.

Stryker is “scouring the market” to see whether Chinese companies can develop new kinds of robots for other parts of the anatomy, he said. He argued that engineering talent isn’t enough in his field without clinical experience. “They can have the best engineers. If they don’t have the domain experience clinically, it’s not going to be so easy,” he said. “So we don’t see them as kind of an imminent threat to our businesses.” Stryker thinks about Chinese companies “more opportunistically,” he said, “and we’re being very thoughtful about not making anything there that can be taken from.”

Lobo said the robot’s value is precision. The surgeon is still in the room, but the Mako arm makes the cuts, following…

Opening of the article, excerpted from Fortune. To read the rest, open the article on the publisher's site.

Read the full article on Fortune Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (fortune.com)

Also worth reading